ALEXION PHARMACEUTICALS, INC.
Customers
0
None disclosed
Suppliers
3
0 disclosed
Latest period
Jun 30, 2025
10-Q filed 2025-08-05
Suppliers 3
Companies that disclose ALEXION PHARMACEUTICALS, INC. as a major customer, as a share of their own revenue. 0 active, 3 lapsed.
| Company | % of their revenue | Est. $ from ALEXION PHARMACEUTICALS, INC. | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. |
22.3% | $24.7M | 3M 2025-06-30 | +7.6pp | Lapsed Last seen 2025-06-30 |
10-Q 2025-08-05 |
As of June 30, 2025 and December 31, 2024, our gross accounts receivable balance was comprised of payments primarily due from license and collaboration agreements with strategic partners and from product sales to customers.The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Bayer (as described in Note 11) * 16.7% 30.1% 61.4% Kyowa Kirin Co., Ltd * 66.2% * 33.8% Alexion (as described in Note 11) 22.3% 14.7% 12.0% * Customer A 19.4% * 15.2% * Customer B 17.5% * 13.7% * Customer C 13.3% * * * Customer D 12.2% * 10.1% * * Represents less than 10% and/or not a customer in the applicable period.We are subject to credit risk from our accounts receivable. | ||||||
| XNCR Xencor Inc |
11.4% | — | 3M 2014-03-31 | Lapsed Last seen 2014-03-31 |
10-Q 2014-05-15 | |
Alexion $ 0.3 11.4 % $ 0.1 12.4 % | ||||||
| HALO HALOZYME THERAPEUTICS, INC. |
1% | $2.0M | FY 2019-12-31 | −2.0pp | Lapsed Last seen 2019-12-31 |
10-K 2020-02-24 |
Alexion 1 % 3 % 13 % | ||||||
Unnamed major customers
Disclosed without names in the fiscal year ending 2020-12-31. Identities are not inferred.
Alerts are coming
Get an email when ALEXION PHARMACEUTICALS, INC.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.